M
Miach Orthopaedics
Privately held company dedicated to developing bio-engineered surgical implants for connective tissue repair, with initial focus on the Bridge-Enhanced™ ACL Repair (BEAR™) Implant
About Miach Orthopaedics
Miach Orthopaedics is a medical device company focused on bio-engineered surgical implants for connective tissue restoration. The company's core product is the Bridge-Enhanced ACL Restoration (BEAR) Implant, a technology developed to treat anterior cruciate ligament (ACL) tears.
Read full description
The BEAR Implant is the first FDA-approved medical technology that enables the body to heal its own torn ACL. Unlike traditional ACL reconstruction, which involves replacing the torn ligament with a graft, the BEAR Implant acts as a bridge to help the ends of the torn ACL heal back together. This approach preserves the patient's native tissue, avoids the complications associated with graft harvesting from other parts of the body, and supports a faster recovery.
The company's business model centers on the sale of this proprietary medical device to hospitals and surgical centers. Its primary clients are orthopedic surgeons specializing in sports medicine. Miach Orthopaedics operates in the competitive orthopedic medical device market, offering a differentiated solution for one of the most common knee injuries.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Boston, United States
- Employees
- 79
- Open positions
- None listed
- Dealroom signal
- 73.7/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, medical implants, Surgery, Spinout, Orthopedic, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Miach Orthopaedics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Apr 2024 | $20M | $150M | Aperture Ventures Partners · SV Health Investors · DSM Venturing · NFLPA | ↗ |
| DEBTDebt | Jan 2023 | $10M | — | Silicon Valley Bank | ↗ |
Growth signals
Latest recorded traffic for Miach Orthopaedics is 29K monthly website visits, up 31.8% over the last three months. Miach Orthopaedics's team grew 2.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Amzak Capital Management- DVDSM Venturing
- AIAmzak Health Investors
Endeavour Vision
Sectoral Asset Management
Amzak Health
Smith & Nephew
NFLPA
Aperture Ventures Partners
SV Health Investors
Mlsplayers
Series B and later1 investor entered at this stage
Other known investors3 additional known investors
Children’s Hospital Boston
Harvard Medical School
Harvard University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Miach Orthopaedics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Miach Orthopaedics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.